Intraoperative management of pulmonary hypertension and associated right heart failure

Current Opinion in Anaesthesiology

Volumn 23, Issue 1, 2010, Pages 49-56

  Gordon, Claire ^a   Collard, Charles D ^a,b   Pan, Wei ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

Intraoperative complications; Pulmonary arterial hypertension; Pulmonary vasodilators; Right heart failure; Surgery

Indexed keywords

BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CITRULLINE; ENDOTHELIN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; ILOPROST; INTRAVENOUS ANESTHETIC AGENT; LEVOSIMENDAN; MILRINONE; NESIRITIDE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN DERIVATIVE; SILDENAFIL; UNIPROST; VARDENAFIL;

CLINICAL ASSESSMENT; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DRUG DOSE TITRATION; HEART RIGHT VENTRICLE FAILURE; HUMAN; INTRAOPERATIVE PERIOD; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW;

CARDIOTONIC AGENTS; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; INTRAOPERATIVE COMPLICATIONS; VASODILATOR AGENTS;

EID: 75149172349     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACO.0b013e3283346c51     Document Type: Review

References (44)

1. Ramakrishna G, Sprung J, Ravi BS, et al. Impact of pulmonary hypertension on the outcomes of noncardiac surgery: predictors of perioperative morbidity and mortality. J Am Coll Cardiol 2005; 45:1691-1699.
2. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association - developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009; 119:2250-2294.
3. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30:2493-2537.
4. Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Cardiol 2008; 51:1527-1538.
5. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54:S43-S54.
6. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation 2004; 109:159-165.
7. Szabo G, Soos P, Bahrle S, et al. Adaptation of the right ventricle to an increased afterload in the chronically volume overloaded heart. Ann Thorac Surg 2006; 82:989-995.
8. Zierer A, Voeller RK, Melby SJ, et al. Impact of calcium-channel blockers on right heart function in a controlled model of chronic pulmonary hypertension. Eur J Anaesthesiol 2009; 26:253-259.
9. Oz MC, Ardehali A. Collective review: perioperative uses of inhaled nitric oxide in adults. Heart Surg Forum 2004; 7:E584-E589.
10. Fujita Y, Nishida O, Sobue K, et al. Nitric oxide inhalation is useful in the management of right ventricular failure caused by myocardial infarction. Crit Care Med 2002; 30:1379-1381.
11. Goyal P, Kiran U, Chauhan S, et al. Efficacy of nitroglycerin inhalation in reducing pulmonary arterial hypertension in children with congenital heart disease. Br J Anaesth 2006; 97:208-214.
12. Barr FE, Tirona RG, Taylor MB, et al. Pharmacokinetics and safety of intravenously administered citrulline in children undergoing congenital heart surgery: potential therapy for postoperative pulmonary hypertension. J Thorac Cardiovasc Surg 2007; 134:319-326.
13. Cabrol S, Souza R, Jais X, et al. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 2007; 26:357-362.
14. Lowson SM. Alternatives to nitric oxide. Br Med Bull 2004; 70:119-131.
15. De Wet CJ, Affleck DG, Jacobsohn E, et al. Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery. J Thorac Cardiovasc Surg 2004; 127:1058-1067.
16. Fattouch K, Sbraga F, Sampognaro R, et al. Treatment of pulmonary hypertension in patients undergoing cardiac surgery with cardiopulmonary bypass: a randomized, prospective, double-blind study. J Cardiovasc Med (Hagerstown) 2006; 7:119-123.
17. Lang I, Gomez-Sanchez M, Kneussl M, et al. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest 2006; 129:1636-1643.
18. Channick RN, Olschewski H, Seeger W, et al. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. J Am Coll Cardiol 2006; 48:1433-1437.
19. Voswinckel R, Enke B, Reichenberger F, et al. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. J Am Coll Cardiol 2006; 48:1672-1681.
20. Fontana M, Olschewski H, Olschewski A, et al. Treprostinil potentiates the positive inotropic effect of catecholamines in adult rat ventricular cardiomyocytes. Br J Pharmacol 2007; 151:779-786.
21. Yurtseven N, Karaca P, Uysal G, et al. A comparison of the acute hemodynamic effects of inhaled nitroglycerin and iloprost in patients with pulmonary hypertension undergoing mitral valve surgery. Ann Thorac Cardiovasc Surg 2006; 12:319-323.
22. Rex S, Missant C, Claus P, et al. Effects of inhaled iloprost on right ventricular contractility, right ventriculo-vascular coupling and ventricular interdependence: a randomized placebo-controlled trial in an experimental model of acute pulmonary hypertension. Crit Care 2008; 12:R113.
23. Winterhalter M, Simon A, Fischer S, et al. Comparison of inhaled iloprost and nitric oxide in patients with pulmonary hypertension during weaning from cardiopulmonary bypass in cardiac surgery: a prospective randomized trial. J Cardiothorac Vasc Anesth 2008; 22:406-413.
24. Hoeper MM, Lee SH, Voswinckel R, et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006; 48:2546-2552.
25. Ewert R, Opitz CF, Wensel R, et al. Continuous intravenous iloprost to revert treatment failure of first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Clin Res Cardiol 2007; 96:211-217.
26. Lewis GD, Shah R, Shahzad K, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007; 116:1555-1562.
27. De Santo LS, Mastroianni C, Romano G, et al. Role of sildenafil in acute posttransplant right ventricular dysfunction: successful experience in 13 consecutive patients. Transplant Proc 2008; 40:2015-2018.
28. Aubin MC, Laurendeau S, Mommerot A, et al. Differential effects of inhaled and intravenous sildenafil in the prevention of the pulmonary endothelial dysfunction due to cardiopulmonary bypass. J Cardiovasc Pharmacol 2008; 51:11-17.
29. Lee JE, Hillier SC, Knoderer CA. Use of sildenafil to facilitate weaning from inhaled nitric oxide in children with pulmonary hypertension following surgery for congenital heart disease. J Intensive Care Med 2008; 23:329-334.
30. Jing ZC, Jiang X, Wu BX, et al. Vardenafil therapy for patients with pulmonary arterial hypertension. A one-year, multicentre, open-label study. Heart 2009; 95:1531-1536.
31. Lamarche Y, Malo O, Thorin E, et al. Inhaled but not intravenous milrinone prevents pulmonary endothelial dysfunction after cardiopulmonary bypass. J Thorac Cardiovasc Surg 2005; 130:83-92.
32. Wang H, Gong M, Zhou B, et al. Comparison of inhaled and intravenous milrinone in patients with pulmonary hypertension undergoing mitral valve surgery. Adv Ther 2009; 26:462-468.
33. Lamarche Y, Perrault LP, Maltais S, et al. Preliminary experience with inhaled milrinone in cardiac surgery. Eur J Cardiothorac Surg 2007; 31:1081-1087.
34. Salzberg SP, Filsoufi F, Anyanwu A, et al. High-risk mitral valve surgery: perioperative hemodynamic optimization with nesiritide (BNP). Ann Thorac Surg 2005; 80:502-506.
35. Jais X, D'Armini AM, Jansa P, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNop- Erable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol 2008; 52:2127-2134.
36. Akagi S, Matsubara H, Miyaji K, et al. Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol. Circ J 2008; 72:1142-1146.
37. Vassallo FG, Kodric M, Scarduelli C, et al. Bosentan for patients with chronic thromboembolic pulmonary hypertension. Eur J Intern Med 2009; 20:24-29.
38. Price LC, Forrest P, Sodhi V, et al. Use of vasopressin after caesarean section in idiopathic pulmonary arterial hypertension. Br J Anaesth 2007; 99:552-555.
39. Poelzl G,Zwick RH, Grander W, et al. Safety and effectiveness of levosimendan in patients with predominant right heart failure. Herz 2008; 33:368-373.
40. Kerbaul F, Rondelet B, Demester JP, et al. Effects of levosimendan versus dobutamine on pressure load-induced right ventricular failure. Crit Care Med 2006; 34:2814-2819.
41. Kerbaul F, Gariboldi V, Giorgi R, et al. Effects of levosimendan on acute pulmonary embolism-induced right ventricular failure. Crit Care Med 2007; 35:1948-1954.
42. Berman M, Tsui S, Vuylsteke A, et al. Life-threatening right ventricular failure in pulmonary hypertension: RVAD or ECMO? J Heart Lung Transplant 2008; 27:1188-1189.
43. Izikki M, Guignabert C, Fadel E, et al. Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. J Clin Invest 2009; 119:512-523.
44. Hirose K, Marui A, Arai Y, et al. Novel approach with intratracheal administration of microgelatin hydrogel microspheres incorporating basic fibroblast growth factor for rescue of rats with monocrotaline-induced pulmonary hypertension. J Thorac Cardiovasc Surg 2008; 136:1250-1256.